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ABSTRACT 
Previous findings demonstrate a homeostatic role for oleoylethanolamide (OEA) 
signaling in the ethanol-related neuroinflammation and behavior. However, extensive 
research is still required in order to unveil the effects of OEA on a number of 
neurobiological functions such as adult neurogenesis, cell survival and resident 
neuroimmunity that become notably altered by alcohol. Daily consumption of ethanol 
(10%) for 2 weeks (6.31.1 g/kg/day during last 5 days) caused hypolocomotor activity 
in rats. This effect appears to rely on central signaling mechanisms given that alcohol 
increased the OEA levels, the gene expression of OEA-synthesizing enzyme Nape-pld 
and the number of PPARα-immunoreactive neurons in the striatum. Ethanol-related 
neurobiological alterations such as a reduction in the number of microglial cells 
expressing iNOS (a cytokine-inducible immune defense) and in adult neural 
stem/progenitor cell (NSPC) proliferation (phospho-H3 and BrdU) and maturation 
(BrdU/β3-tubulin), as well as an increase in damage cell activity (FosB) and apoptosis 
(cleaved caspase 3) were also observed in the rat striatum. Pharmacological 
administration of OEA (10 mg/kg) for 5 days during ethanol exposure exacerbated 
ethanol-induced hypolocomotion and cell apoptosis in the striatum. Interestingly, OEA 
abrogated the impaired effects of ethanol on PPARα+ cell population and NSPC 
proliferation and maturation. OEA also decreased astrocyte activation (vimentin) and 
increased microglial activation (Iba-1, iNOS) in the striatum. These results suggest that 
OEA-PPARα signaling modulates glial activation, cell apoptosis and NSPC 
proliferation and maturation in response to striatal-specific neurobiological alterations 
induced by prolonged ethanol intake in rats. 
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1. INTRODUCTION 1 
The satiety factor oleoylethanolamide (OEA), a structural analogue of the N-acylethanolamine 2 
(NAE) arachidonoyl ethanolamide (AEA or anandamide), is a bioactive lipid mediator that 3 
exerts a number of pharmacological effects on lipid and glucose metabolism, energy 4 
expenditure and satiety/motivated responses to dietary fat, through the highly potent 5 
activation of the peroxisome proliferator-activated receptor-alpha (PPARα) (Guzmán et al., 6 
2004; Piomelli, 2013; Suárez et al., 2014; Bilbao et al., 2016). The intestine is able to produce 7 
OEA upon the input of fat-containing food, a process that activates peripheral sensory 8 
systems (vagus nerve), informs to central integrative networks (solitary tract nucleus and 9 
hypothalamus) and releases gut peptides into blood in order to regulate energy expenditure 10 
(Fu et al., 2011; Serrano et al., 2011). Moreover, growing evidence indicates that OEA serves 11 
as a hedonic homeostatic signal in motivated and cognitive processes through the reward and 12 
limbic systems in the brain (Campolongo et al., 2009; Rivera et al., 2014), involving food 13 
selection (Tellez et al., 2013), dopaminergic responses associated with nicotine-independent 14 
mechanism (Mascia et al., 2011) and alcohol-seeking behavior (Bilbao et al., 2016). 15 
A recent study of our group has identified a relevant role of OEA as a homeostatic signal that 16 
influences physiological adaptations to alcohol exposure (Bilbao et al., 2016). Alcohol 17 
administration triggers OEA production that, in turn, regulates behavioral effects such as 18 
motivational response to alcohol and withdrawal symptoms after cessation of alcohol 19 
consumption. As a confirmation, it was found that the administration of OEA (5 and 20 20 
mg/kg) and other PPARα agonists (gemfibrozil, Wy 14643, tesaglitazar, and fenofibrate) 21 
reduced alcohol intake and self-administration, an effect that depends on PPARα activation 22 
(Barson et al., 2009; Ferguson et al., 2014; Bilbao et al., 2016). OEA mobilization following 23 
acute alcohol exposure was first observed in the jejunum and nucleus accumbens (Bilbao et 24 
al., 2016). Peripherally, alcohol-enhanced sympathetic activity could be responsible for OEA 25 
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mobilization in the intestine and in metabolically-relevant organs such as adipose tissue 26 
(LoVerme et al., 2006; Fu et al., 2011). Centrally, alcohol may trigger receptor-dependent 27 
OEA activation through the NAPE-PLD pathway (Stella and Piomelli, 2001; Spanagel, 2009). 28 
A rapid response of the nucleus accumbens to alcohol may be related to the recruitment of 29 
either catecholaminergic, cholinergic and/or glutamatergic neurons (Spanagel, 2009). 30 
Moreover, as it was previously described for fats and high-caloric foods (Piomelli, 2013), our 31 
hypothesis suggests that the satiety factor OEA is also able to modulate motivational 32 
responses to alcohol. In this regard, OEA and other PPARα agonists decreased cue-induced 33 
reinstatement of alcohol consumption (Bilbao et al., 2016). This relevant result implies that 34 
OEA is capable of controlling contextual memories associated with alcohol relapse. In 35 
addition, alcohol withdrawal symptoms are supported by the decrease in OEA levels and its 36 
adaptive nature as a homeostatic signal (Bilbao et al., 2016). Interestingly, OEA injection at 37 
the beginning of withdrawal (when OEA levels are dropping) produced a lower severity of the 38 
withdrawal symptoms. These results support previous clinical studies suggesting that OEA 39 
levels are altered in alcohol-dependence during abstinence and might be a potential marker for 40 
predicting length of alcohol abstinence (García-Marchena et al., 2017). Human genetic reports 41 
also described an association between alcohol use disorders and polymorphisms/mutation of 42 
the gene encoding the NAE-hydrolyzing enzyme fatty acid amide hydrolase (FAAH) (Sipe et 43 
al., 2002). 44 
The endogenous lipid mediators NAEs share common biosynthetic and degradative pathways 45 
but not receptor targets (i.e. AEA on the cannabinoid CB1 and CB2 receptors; OEA on 46 
PPARα) (Overton et al., 2006; Pertwee, 2008; Ueda et al., 2010; Di Marzo et al., 2011). The 47 
NAE signaling systems can be targeted by drugs of abuse (Orio et al., 2013) and, in turn, may 48 
mediate neuroprotective effects on alcohol-induced neurodegeneration and cognitive deficits 49 
triggered by neuronal cell death and loss of neurogenesis (Nixon and Crews, 2004; Rivera et 50 
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al., 2015b). Consequently, alcoholics show significant volume loss in cortical and subcortical 51 
brain structures that includes both gray and white matter shrinkage (Crews and Nixon, 2009). 52 
In this regards, NAEs may be of interest as they can act on the neuronal stem cells 53 
proliferation (Stella, 2010; Katona and Freund, 2012; Galve-Roperh et al., 2013; Bandiera et 54 
al., 2014; Rivera et al., 2015b). However, one of the major concerns that have been raised 55 
against the use of CB1 receptor agonists arises from results showing that these compounds 56 
may increase the intake of drugs of abuse, especially alcohol (Colombo et al., 2005). An 57 
alternative to pharmacological cannabinoid activation could be the selective inhibition of 58 
FAAH, the primary enzyme responsible for the degradation of AEA, as it does not increase 59 
alcohol abuse risk and reduces anxiety associated to alcohol withdrawal (Cippitelli et al., 60 
2008). However, the inhibition of FAAH did not promote adult neurogenesis in alcoholic rats 61 
(Rivera et al., 2015b), despite its known effects on neural proliferation in culture and healthy 62 
rodent (Aguado, et al., 2005; Goncalves et al., 2008; Rivera et al., 2015a), as well as 63 
neuroprotection from brain injury (Fowler et al., 2010). 64 
Because PPARα stimulation might be of potential interest for alcohol dependence (Ferguson 65 
et al., 2014; Bilbao et al., 2016), a promising therapy to potentiate central mechanisms leading 66 
to neuroprotective and anti-inflammatory effects might be the direct administration of OEA 67 
binding to PPARα (Anton et al., 2016). However, at present, it is unclear the neurobiological 68 
mechanisms underlying the homeostatic role of OEA-PPARα signaling in the ethanol-related 69 
neurodegeneration and behavior such as adult neurogenesis, cell survival and resident 70 
neuroimmune cells. To shed light on these questions, the present study was designed to 71 
investigate the pharmacological effects of the repeated administration (5 days) of OEA (10 72 
mg/kg), contrasted with those of AEA (10 mg/kg), on astrogliosis (GFAP, vimentin) and 73 
microgliosis (Iba-1, iNOS), as well as cell proliferation (phospho-H3, BrdU), maturation 74 
(BrdU/β3-tubulin) and apoptosis (cleaved caspase-3) in the striatum and its neurogenic zone, 75 
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the subventricular zone of the lateral ventricles (SVZ), of the adult rats with a daily 76 
consumption of alcohol (10%) in diet for two weeks. 77 
 78 
2. MATERIALS AND METHODS 79 
2.1. Ethics Statement 80 
The protocols for animal care and use were approved by the Ethics and Research Committee 81 
at the Hospital Universitario Regional de Málaga and Universidad de Málaga. All 82 
experimental animal procedures were carried out in strict accordance with the European 83 
Communities directive 86⁄609⁄ECC (24 November 1986) and Spanish legislation (BOE 84 
252⁄34367-91, 2005) regulating animal research. All efforts were made to minimize animal 85 
suffering and to reduce the number of animals used. 86 
 87 
2.2. Animals 88 
Male Wistar rats (approximately 250 g, 10–12 weeks old; Charles Rivers, Barcelona, Spain) 89 
were housed individually in cages maintained in standard conditions (Centro de 90 
Experimentación Animal, Universidad de Málaga) at 20 ± 2 ºC room temperature, 40 ± 5% 91 
relative humidity and a 12-h light⁄dark cycle with dawn⁄dusk effect. Water and standard 92 
rodent chow (Prolab RMH 2500, 2.9 kcal/g) were available ad libitum, unless otherwise 93 
indicated for specific experimental procedures. 94 
 95 
2.3. Alcoholic diet habituation 96 
Seventy-two animals were daily weighed, handled for 10 minutes and habituated to injection 97 
procedures (holding and pseudo-injection) during one week before the experimentation in 98 
order to minimize stress effects. To habituate the animals to feeding procedures, rats were 99 
first food-deprived to 95% of their free-feeding weight and then they were allowed ad libitum 100 
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access to a complete and balanced chocolate-flavored liquid food (0.97 kcal/mL; Glucerna 101 
SR, Abbott Laboratories, Madrid, Spain) until a stable rate of feeding was reached (~50 102 
mL/day, up to 2-3 days). Then, the rats were divided into two groups (n=36) and fed with the 103 
chocolate-flavored liquid diet supplemented with 11% (v/v) ethanol 96º (alcoholic liquid diet) 104 
or 14.7% (w/v) sucrose (sucrose liquid diet) (Serrano et al., 2012). Both alcoholic and sucrose 105 
liquid diets were formulated to contain the same calories (1.4 kcal/mL). Thus, the same 106 
volume of ethanol liquid diet consumed ad libitum was given the next day to the rats fed with 107 
the sucrose liquid diet. The rats were maintained under a controlled-isocaloric per feeding 108 
period until a stable rate of alcoholic feeding was reached (~30 mL/day, up to one week). In 109 
any case, standard rodent chow was not given, but water was available ad libitum, during the 110 
experimentation. Caloric intake and body weight were periodically monitored.  111 
 112 
2.4. Administration of OEA and AEA 113 
After alcoholic diet habituation, the rats were fed ad libitum with both liquid diets (ethanol or 114 
sucrose) and treated with the endogenous PPARα and GPR55 receptor agonist OEA 115 
(oleoylethanolamide; cat. no. 1484, Tocris, Abingdon, UK) and the endogenous cannabinoid 116 
and TRPV1 receptor agonist AEA (anandamide; cat. no. 1339, Tocris). Drugs were dissolved 117 
in a vehicle containing 33% (v/v) DMSO in sterile 0.9% NaCl solution, just before each 118 
experiment, and were intraperitoneally (i.p.) injected in a final volume of 1 mL/kg of body 119 
weight. The optimal dose at which treatment would be more effective in neuroprotection, as 120 
described previously (Piomelli et al., 2006; Galán-Rodríguez et al., 2009), was selected for 121 
the present study. Thus, OEA and AEA were repeatedly administrated at a dose of 10 mg/kg 122 
body weight, for 5 consecutive days at intervals of 24 hours (08:00 a.m.). The animals were 123 
sacrificed 2 hours after the last injection of the drugs. Finally, we obtained six experimental 124 
groups depending on the diet and treatment (n=12): vehicle-treated sucrose-fed group, AEA-125 
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treated sucrose-fed group, OEA-treated sucrose-fed group, vehicle-treated ethanol-fed group, 126 
AEA-treated ethanol-fed group and OEA-treated ethanol-fed group. 127 
 128 
2.5. BrdU administration  129 
5´-bromo-2´-deoxyuridine (BrdU; cat. no. B5002, Sigma, St. Louis, MO, USA) was dissolved 130 
at 15 mg⁄mL in sterile 0.9% NaCl solution. During the ad libitum feeding period, BrdU was 131 
i.p. administrated at a dose of 50 mg/kg of body weight, twice per day at intervals of 10 hours 132 
(08:00, 18:00 h), for 4 consecutive days (Rivera et al., 2015b). 133 
 134 
2.6. Open field test 135 
For this behavioral protocol, we used a four square Open Field (OF) (L50 × W50 × H50 cm) 136 
mazes during treatment (Panlab, Barcelona, Spain). Arenas were uniformly illuminated with 137 
light intensities of 50 lux at the centers of the arenas. The apparatuses were cleaned between 138 
sessions with 70% ethanol and then dried. Behavioral tests were carried out between 8:00 and 139 
15:00. Each animal was treated and, 30 minutes later, placed individually in the center of each 140 
arena, and the locomotor activity was recorded with a video tracking system (Smart®, 141 
Panlab). The testing orders of the treatment groups were counterbalanced to avoid 142 
confounding effects of the time of the day at which the animals were tested. Locomotor 143 
activity was assessed by measuring the distance traveled (cm) for three time bins of 5 minutes 144 
each one.  145 
 146 
2.7. Sample collection 147 
Prior to sacrifice, all animals were anaesthetized (sodium pentobarbital, 50 mg/kg body 148 
weight, i.p.) two hours after the last dose of treatment in a room separate from the other 149 
experimental animals. The blood samples were transcardially collected into tubes containing 150 
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EDTA-2Na (1 mg/mL blood) and centrifuged (1600 g for 10 min, 4ºC). The plasma samples 151 
were then frozen and stored at -80ºC for biochemical and liquid chromatography–multiple 152 
reaction monitoring (LC-MRM) analyses.  153 
The first batch of animals (n = 6/group) were sacrificed by decapitation and their brains were 154 
collected, snap-frozen and stored at −80°C. These brains were then prepared on dry ice to 155 
obtain sections of 1 mm thick by using razor blades and a rat brain slicer matrix. The striatum 156 
were precisely removed from 2.20 to −0.26 mm of Bregma levels (Paxinos and 157 
Watson, 2007) with fine surgical instruments. Brain samples were weighed and stored at 158 
−80°C until they were used for RT-qPCR and LC-MRM analysis. The second batch of 159 
animals (n = 6/group) were transcardially perfused with 4% formaldehyde in 0.1 M phosphate 160 
buffer (PB) and the brains were dissected out and kept in the same fixative solution overnight 161 
at 4ºC. The brains were then cut into 30-μm-thick coronal sections by using a sliding 162 
microtome (Leica VT1000S) and divided in 12 parallel series. Sections were stored at 4ºC in 163 
PB with 0.002% (w/v) sodium azide until they were used for immunostaining. 164 
 165 
2.8. N-acylethanolamine quantification 166 
The quantitative analysis of OEA and AEA in plasma followed the protocols previously 167 
published (Lomazzo et al., 2014; Bindila and Lutz, 2016) with a brief modification. After 168 
resuspension of endocannabinoid extract in 50 µL (1:1, ACN:H20), sample aliquots were 169 
prepared by diluting 1:5 in (1:1 v/v, ACN:H20) prior to injection in the LC/MRM. Twenty µL 170 
of the aliquots were injected into the LC/MRM. The brain and plasma endocannabinoid 171 
concentrations were normalized to tissue weight and to plasma volume, respectively. 172 
 173 
2.9. Ethanol concentration and hepatic enzyme activity in blood 174 
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The blood ethanol concentration (BEC) was determined using the alcohol oxidase method 175 
with an AM1 Alcohol Analyzer (Analox Instrument, London, UK). The activity of the hepatic 176 
enzymes gamma-glutamyl transpeptidase (GT), glutamate pyruvate transaminase (GPT) and 177 
glutamic oxaloacetic transaminase (GOT) were analyzed using commercial kits according to 178 
the manufacturer´s instructions in a Hitachi 737 Automatic Analyzer (Hitachi Ltd., Tokyo, 179 
Japan). A calibration curve and internal controls were included in each assay. 180 
 181 
2.10. RNA isolation and RT-qPCR analysis 182 
We performed real-time PCR (TaqMan, ThermoFisher Scientific, Waltham, MA, USA) as 183 
was described previously (Rivera et al., 2015a) using specific sets of primer probes (Cnr1: 184 
Rn02758689_s1, Amplicon length: 92; Pparα: Rn00566193_m1, Amplicon length: 98; Nape-185 
pld: Rn01786262_m1, Amplicon length: 71; Faah: Rn00577086_m1, Amplicon length: 63; 186 
Actb: Rn00667869_m1, Amplicon length: 91; ThermoFisher Scientific). Briefly, the striati 187 
were homogenized on ice and the RNA was extracted following Trizol® method according to 188 
the manufacture's instruction (Gibco BRL Life Technologies, Baltimore, MD, USA). The 189 
RNA samples were isolated with RNAeasy minelute cleanup-kit including digestion with 190 
DNase I column (Qiagen, Hilden, Germany). After reverse transcript reaction from 1 μg of 191 
RNA, quantitative real-time reverse transcription polymerase chain reaction (qPCR) was 192 
performed in a CFX96TM Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) 193 
and the FAM dye label format for the TaqMan® Gene Expression Assays (ThermoFisher 194 
Scientific). Melting curve analysis was performed to ensure that only a single product was 195 
amplified. After analyzing several control genes, values obtained from the brain samples were 196 
normalized in relation to β-actin (Actb) levels. 197 
 198 
2.11. Immunohistochemistry 199 
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Free-floating coronal sections (n= 6-7) from one of the 12 parallel series obtained from each 200 
rat striatum were selected from 2.20 to −0.26 mm of Bregma levels (Paxinos and 201 
Watson, 2007) to perform each immunolabeling. For immunohistochemistry, sections were 202 
incubated overnight in the following diluted primary antibody at 4°C: mouse anti-glial 203 
fibrillaric acidic protein (GFAP) (1:500; cat. no. G3893, Sigma), mouse anti-vimentin (1:500; 204 
cat no. V6630, Sigma), rabbit anti-Iba-1 (1:1000; cat. no. 019-19741, Wako, Neuss, 205 
Germany), rabbit anti-iNOS (1:500, ThermoFisher, cat no. PA1-036), rabbit anti-FosB 206 
(1∶2500; cat. no. sc-48, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-cleaved 207 
caspase-3 (1:500; cat. no. 9661, Cell Signaling, Leiden, The Netherlands), rabbit anti-208 
phospho-histone H3 (Ser10) (2 μg/mL; cat. no. 06-570, Merck, Madrid, Spain), and mouse 209 
anti-BrdU (1:2000; cat. no. G3G4, Hybridoma Bank, Iowa City, IA, USA) (Rivera et al., 210 
2013). 211 
The following day the sections were incubated in the respective secondary antibody for 90 212 
minutes: biotinylated goat anti-mouse IgG (1:500; cat. no. B7264, Sigma) or biotinylated 213 
donkey anti-rabbit IgG (1:500; cat. no. RPN1004, Amersham, Little Chalfont, England). The 214 
sections were then incubated in ExtrAvidin peroxidase (Sigma) diluted 1:2000 in darkness at 215 
room temperature for 1 hour. Finally, immunoreactivity was revealed with 0.05% 216 
diaminobenzidine (DAB; Sigma), 0.05% nickel ammonium sulfate and 0.03% H2O2 in PBS. 217 
 218 
2.12. Immunofluorescence 219 
The following antibodies were used: mouse anti-PPARα (1:200; cat. no. 20R-PR21, 220 
Fitzgerald, Acton, MA, USA), rabbit anti-cleaved caspase-3 (1:500; cat. no. 9661, Cell 221 
Signaling), mouse anti-Iba-1 (1:500; cat. no. MABN92, Merck), mouse anti-GFAP (1:500; 222 
cat. no. G3893, Sigma), rat anti-BrdU (1:2000; cat. no. OBT0030G, Accurate Chemical and 223 
Scientific, Westbury, NY, USA), and mouse anti-β3 tubulin (1:5000; Promega, Madison, WI, 224 
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USA). For double immunofluorescence, sections were incubated overnight at 4°C with a 225 
cocktail of the primary antibodies and then with the correspondent secondary antibodies: 226 
donkey anti-rat IgG (H+L) labeled with Alexa Fluor® 488 (1:1000; cat. no. A21208, 227 
Molecular Probes, Invitrogen, Paisley, UK), donkey anti-mouse IgG (H+L) labeled with 228 
Alexa Fluor® 594 (1:1000; cat. no. A21203, Molecular Probes), and donkey anti-rabbit IgG 229 
labeled with Cy3 bis-NHS ester (1:300; cat. no. 711-166-152, Jackson ImmunoResearch). 230 
 231 
2.13. Cell counting 232 
Positive (+) immunoreactive and immunofluorescent nuclei and cells that came into focus 233 
were manually counted. Representative counting frames from sections with immunoreactivity 234 
were evaluated using a standard optical microscope with the 40× objective (Nikon 235 
Instruments Europe B.V., Amstelveen, The Netherlands) coupled to the NIS-Elements 236 
Imaging Software 3.00 (Nikon). For immunofluorescent cell counting, the sections were 237 
visualized with a confocal laser (spectral) scanning microscope (Leica TCS NT; Leica 238 
Microsystems) equipped with a 561 nm DPM laser (argon 30%) and a 40× objective (HCX 239 
PL APO CS 40.0x1.25 OIL UV). The emission filter settings were 500–550 nm for PMT2 240 
(green) and 610–700 nm for PMT3 (red). Depending on the level of zoom used in each image, 241 
the XY voxel size was from 100 to 77 nm, approximately. Settings of light and 242 
brightness/contrast were adjusted by using the Leica LAS AF Lite imaging software. 243 
Phospho-H3+ and BrdU+ nucleus counts were performed in the subventricular zone (SVZ) of 244 
the lateral ventricles, while GFAP, Iba-1, iNOS, FosB, cleaved caspase-3 and PPARα+ cell 245 
counts were carried out in the whole striatum. Overall, quantification was expressed as the 246 
average number of cells per area (mm
2
) for each experimental group. 247 
 248 
2.14. Statistical analysis 249 
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Statistical analysis of the results was performed using the computer program GraphPad Prism 250 
version 5.04 (GraphPad Software Inc., San Diego, CA, USA). Data were represented as the 251 
mean + s.e.m. for at least six determinations per experimental group. Kolmogorov-Smirnov 252 
normality tests indicated that all data followed a Gaussian distribution (P>0.1), so we selected 253 
a parametric statistical test. Statistical analysis was performed using one-way ANOVA and 254 
two-way ANOVA with the two factors being diet or treatment and time, followed by 255 
Bonferroni post hoc test for multiple comparisons, or Student’s t test when appropriate. 256 
P<0.05 was considered to be significant. 257 
 258 
3. RESULTS 259 
3.1. Ethanol consumption 260 
Rats were habituated to a controlled-isocaloric pair-feeding period of sucrose and alcohol 261 
diets for 10 days (Fig. 1A). During the habituation period, daily consumption of ethanol 262 
(10%) in diet reached up to 12.5 ± 1.4 g of ethanol/kg body weight/day. Then, all rats were 263 
exposed ad libitum to the diets for 6 days. During the ad libitum feeding period, daily 264 
consumption of ethanol in diet reached an average of 6.31.1 g/kg/day. We observed an effect 265 
of alcohol (F1,60= 1104.42, P< 0.0001) and time (F5,60= 204.81, P< 0.0001) on diet 266 
consumption, and an interaction between factors (F5,60= 97.58, P< 0.0001). The main results 267 
indicated that the ad libitum consumption of the alcoholic diet, measured as cumulative 268 
intake, was lower than that of the sucrose liquid diet from the day 11 onward (day 11, 269 
**P<0.01; day 12 on, ***P<0.001) (Fig. 1B). 270 
 271 
3.2. Effect of ethanol consumption on locomotor activity 272 
We investigated the impact of the ethanol consumption on the locomotor activity (distance 273 
travelled for three time bins of 5 minutes each one) by using an Open Field paradigm. We 274 
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observed an effect of alcohol (F1,10= 13.22, P= 0.01) and time (F2,20= 14.12, P= 0.001) on the 275 
distance covered for 15 minutes. The main results indicated that rats exposed to alcoholic diet 276 
showed a lower distance travelled in the Open Field compared to that of the sucrose group 277 
over the 3 time bins of 5 minutes each (*P<0.05) (Fig. 1C). 278 
 279 
3.3. Effects of ethanol consumption on hepatic enzyme activity in plasma 280 
To evaluate the alcohol-associated toxicity we measured the blood ethanol concentration 281 
(BEC) and the activity of the hepatic enzymes gamma-glutamyl transpeptidase (γGT), 282 
glutamate pyruvate transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) in 283 
plasma. No difference in BEC was found between rats fed with sucrose and alcoholic diet; 284 
probably due to a clearance effect during the time spent between the last alcohol intake and 285 
the BEC analysis (Fig. 1D). However, rats exposed to alcoholic diet showed higher 286 
GPT/GOT ratio and GT plasma levels that those of the sucrose group (*P<0.05) suggesting 287 
hepatic toxicity induced by chronic alcohol consumption (Fig. 1D). 288 
  289 
3.4. Effect of ethanol consumption on the N-acylethanolamine levels in plasma and brain 290 
We analyzed the levels of the N-acylethanolamines (NAE) OEA and AEA in the plasma (Fig. 291 
1D) and the brain regions striatum, hippocampus and hypothalamus (Fig. 1E) of rats exposed 292 
to sucrose and ethanol. Alcoholic diet induced an increase in the plasma levels of AEA 293 
(**P<0.01), but not OEA (Fig. 1D). However, both OEA and AEA levels were specifically 294 
augmented in the striatum (*P<0.05), but not in the hippocampus and hypothalamus, of rats 295 
exposed to alcoholic diet (Fig. 1E). 296 
 297 
3.5. Effects of ethanol consumption on the mRNA levels of the NAE-metabolizing 298 
enzymes and NEA receptors in the striatum 299 
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As we found alterations of OEA and AEA levels in the striatum, we analyzed the gene 300 
expression of the main NAE-related machinery (Nape-pld and Faah) and receptors (Cnr1 and 301 
Pparα). We observed an increase in the mRNA levels of Nape-pld in the striatum of ethanol-302 
exposed rats compared with those of sucrose group (*P<0.05) (Fig. 1F). No changes were 303 
found in the striatal gene expression of Cnr1, Pparα and Faah. 304 
 305 
3.6. Effect of OEA and AEA on ethanol consumption 306 
OEA and AEA were pharmacologically administered (10 mg/kg) during 5 days and the 307 
dietary sucrose or ethanol consumption was evaluated (Fig. 2A). Our results indicated an 308 
effect of OEA on sucrose diet consumption (F1,50= 31.89, P< 0.0001), but not ethanol diet 309 
consumption. However, we found AEA effects on both sucrose (F1,50= 350.13, P< 0.0001) 310 
and ethanol (F1,50= 9.91, P= 0.002) diet consumption. Time effects were also observed on 311 
both sucrose and ethanol diet consumption of rats treated with OEA and AEA for 5 days 312 
(F4,50> 15.01, P< 0.0001). Interaction between treatment (OEA and AEA) and time was found 313 
in rats exposed to sucrose diet (F4,50> 8.6, P< 0.0001), but not in rats exposed to ethanol diet. 314 
Post-hoc analysis indicated that OEA induced an increase in sucrose diet intake on the third 315 
and fourth day of treatment (***P<0.001) (Fig. 2B). AEA also induced an increase in sucrose 316 
diet intake from the third day onwards (***P<0.001). 317 
 318 
3.7. Effect of OEA and AEA on locomotor activity  319 
We investigated the impact of OEA and AEA in the locomotor activity of rats exposed to 320 
ethanol in diet (Fig. 2D-F). Rats exposed to sucrose or ethanol in diet and treated with OEA 321 
or AEA exhibited a lower distance covered in the Open Field compared to those of the 322 
respective vehicle-treated group (sucrose: */**P<0.05/0.01; ethanol:
 #
P<0.05) (Fig. 2E). The 323 
OEA-induced decrease in the locomotor activity was exacerbated in rats exposed to ethanol 324 
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diet compared to that of the OEA-treated sucrose group (
$
P<0.05). However, no difference in 325 
locomotor activity between rats exposed to sucrose and ethanol diet was found when they 326 
were treated with AEA (Fig. 2E). 327 
Regarding the alcoholic diet groups, OEA administration induced a decrease in the distance 328 
covered during the first 10 minutes of the Open Field test (
#
P<0.05) (Fig. 2E), while AEA 329 
treatment only produced a decrease in the distance travelled during the first 5 minutes 330 
(
#
P<0.05) (Fig. 2F). The influence of OEA and AEA on the locomotor activity disappear 331 
during the last 5 minutes of test. 332 
 333 
3.8. Effects of OEA and AEA on hepatic enzyme activity and NAE levels in plasma 334 
To evaluate the treatment effect on ethanol-associated toxicity, we analyzed the activity of the 335 
hepatic enzymes γGT, GPT and GOT in the plasma of rats exposed to the alcoholic diet. Our 336 
results indicated that OEA administration specifically decreased the GPT/GOT ratio in rats 337 
exposed to ethanol (
#
P<0.05) (Fig. 2G). Neither OEA or AEA modified the plasma activity of 338 
GT. The levels of AEA and OEA remained high in plasma at the moment of sacrifice, 2 339 
hours after the last administration, in AEA-treated rats and OEA-treated rats, respectively 340 
(
#
P<0.05) (Fig. 2H). Interestingly, we also observed an increase in the plasma levels of AEA 341 
in OEA-treated rats exposed to the alcoholic diet (
#
P<0.05) (Fig. 2H). However, AEA-treated 342 
rats exposed to ethanol did not exhibited significant changes in the plasma levels of OEA. 343 
 344 
3.9. Effect of OEA and AEA on gliosis in the striatum of ethanol-exposed rats 345 
To investigate the impact of OEA and AEA on astroglial and microglial activity in the 346 
striatum of ethanol-exposed rats, we evaluated the number of immunoreactive cells for GFAP, 347 
Iba-1 and iNOS, as well as vimentin immunoreactivity by densitometry (Fig. 3). Regarding 348 
astrogliosis, no ethanol effects were found on the number of GFAP+ cells and vimentin 349 
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immunoreactivity (Fig. 3A-J). Regarding microgliosis, we didn’t observe changes in the 350 
number of Iba1+ cells, but we detected a decrease in the number of iNOS+ cells in the 351 
striatum of ethanol-exposed rats (*P<0.05) (Fig. 3K-T). The striatum of the rats exposed to 352 
an alcoholic diet and treated with OEA or AEA showed higher number of GFAP+ and Iba-1+ 353 
cells compared to that of the ethanol-vehicle group (
##/###
P<0.01/0.001) (Fig. 3A,K). In 354 
contrast, OEA induced a decrease in the striatal levels of vimentin immunoreactvity (
#
P<0.05) 355 
(Fig. 3F-J), and an increase in the number of the striatal iNOS+ cells of rats exposed to 356 
ethanol (
#
P<0.05) (Fig. 3P-T). 357 
 358 
3.10. Effect of OEA and AEA on cell damage and apoptosis in the striatum of ethanol-359 
exposed rats 360 
Alcohol consumption in diet induced an increase in the number of immunoreactive cells for 361 
the cell damage marker FosB and the cell apoptotic factor cleaved caspase 3 (**P<0.01) (Fig. 362 
4A,F). Regarding treatment during alcoholic diet, no changes were found in the number of 363 
FosB+ cells in the striatum of OEA and AEA-treated rats (Fig. 4A-E). We observed a 364 
significant increase in the number of cleaved caspase 3+ cells in the striatum of the rats 365 
treated with OEA compared to those of ethanol-vehicle group (
#
P<0.05) (Fig. 4F-J). 366 
 367 
3.11. Effect of OEA and AEA on apoptotic phenotyping of glial cells in the striatum of 368 
ethanol-exposed rats 369 
We evaluated the number of astroglial and microglial cells expressing the apoptotic factor 370 
cleaved caspase 3 (Fig. 5). Our results showed that ethanol consumption induced a decrease 371 
in the number of cleaved caspase 3+ cells expressing Iba-1 (**P<0.01), but not GFAP, in the 372 
striatum (Fig. 5A-F). Curiously, we found a reduction in the number of GFAP+/cleaved 373 
caspase 3+ cells in the striatum of ethanol-exposed rats treated with OEA (
#
P<0.05) (Fig. 5A-374 
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E). No effects of OEA and AEA were observed on the number of Iba-1+/cleaved caspase 3+ 375 
cells (Fig. 5F-J). 376 
 377 
3.12. Effect of OEA and AEA on PPARα expression in the striatum of ethanol-exposed 378 
rats 379 
As a high number of striatal neurons express PPARα, the main OEA receptor, we evaluated 380 
whether OEA and AEA can affect the presence and survival of PPARα+ cells as well as their 381 
putative expression in microglial cells. Ethanol consumption in diet induced an increase in the 382 
number of striatal PPARα+ cells (Fig. 6A-C) and a reduction in the number of PPARα+ cells 383 
expressing the apoptotic factor cleaved caspase 3 (*/***P<0.05/0.001) (Fig. 6F-H). Both 384 
OEA and AEA completely counteracted the ethanol effect on the number of PPARα+ cells 385 
(
###
P<0.001) (Fig. 6A-E), but not on PPARα+ cell survival (Fig. 6F-J) or PPARα+ cells 386 
expressing Iba-1 (Fig. 6K-O). 387 
 388 
3.13. Effect of OEA and AEA on cell proliferation in the subventricular zone of ethanol-389 
exposed rats 390 
The subventricular zone (SVZ) of the lateral ventricles is a relevant neurogenic niche of the 391 
adult striatum. We evaluated the number of newborn cells in the SVZ by the analysis of the 392 
mitosis-related protein phospho (Ser-10)-histone H3 and after the administration of BrdU (50 393 
mg/kg) for 4 days (Fig. 7). Phosphorylation at the residue Ser-10 in the histone H3 is 394 
considered a crucial event for the onset of mitosis. BrdU, a synthetic nucleoside that is an 395 
analog of thymidine, can be incorporated into the newly synthesized DNA of replicating cells. 396 
The number of phospho-H3+ cells and BrdU+ cells were decreased in the SVZ of rats 397 
exposed to ethanol (*P<0.05) (Fig. 7A-J). Interestingly, OEA counteracted the deleterious 398 
effect of ethanol as it specifically increased the number of phospho-H3+ cells and BrdU+ 399 
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cells in the SVZ of rats exposed to ethanol (
##
P<0.01) (Fig. 7A-J). No effects of AEA on cell 400 
proliferation in SVZ were found. 401 
 402 
3.14. Effect of OEA and AEA on cell phenotyping of the newborn cells in the SVZ of 403 
ethanol-exposed rats 404 
To phenotype the newborn cells in the SVZ, we evaluated the number of BrdU+ cells 405 
showing a precursor (GFAP) or mature (3-tubulin) neuronal, or microglial (Iba-1) 406 
phenotype. No significant changes were observed in the number of BrdU+ cells expressing 407 
GFAP in rats exposed to ethanol (Fig. 8A-E). However, rats exposed to alcoholic diet showed 408 
a lower number of BrdU+ cells expressing 3-tubulin (*P<0.05) (Fig. 8F-J) and Iba-1 409 
(***P<0.001) (Fig. 8K-O) compared to those of the sucrose group. Both OEA and AEA 410 
specifically induced an increase in the number of BrdU+ cells expressing 3-tubulin that 411 
counteracted the deleterious effect of ethanol (
#/##
P<0.05/0.01) (Fig. 8F). 412 
 413 
4. DISCUSSION 414 
PPARα agonists are anti-inflammatory, neuroprotective and have anti-addictive properties 415 
(Anton et al., 2016; Bilbao et al., 2016). Particularly, recent evidence suggests that drugs 416 
targeting PPARα can be effective in treating alcohol dependence among other addictions 417 
(Plaza-Zabala et al., 2010; Le Foll et al., 2013; Ferguson et al., 2014; Bilbao et al., 2013, 418 
2016). Bilbao and collaborators (2016) demonstrated an enhancement of OEA mobilization in 419 
the nucleus accumbens after ethanol administration, which in turn reduced alcohol 420 
consumption by activating PPARα. In addition, a decrease in OEA levels was associated with 421 
alcohol withdrawal symptoms. The acute i.p. administration of OEA (5 mg/kg) confirmed the 422 
reduction of alcohol intake and self-administration, and blocked cue-induced reinstatement of 423 
alcohol-seeking behavior and somatic withdrawal symptoms after cessation of alcohol 424 
18 
 
consumption (Bilbao et al., 2016). These results suggested that OEA acts as an endogenous 425 
signal that modulates the homeostatic adaption of alcohol, including multiple physiological 426 
aspects and behavioral symptoms associated with motivation that extend to the control of 427 
contextual memories. In our rat model of daily exposure of ethanol added in diet (10%) for 2 428 
weeks, the repeated administration of OEA (10 mg/kg) for the last 5 days of ethanol exposure 429 
didn’t increased ethanol intake, as was observed for AEA and ACEA (present study; Rivera et 430 
al., 2015b). Interestingly, we found that OEA, as well as AEA, increased the ethanol-induced 431 
hypolocomotion. A previous study also described that the pharmacological administration of 432 
the synthetic PPARα activator fenofibrate after weaning during ethanol withdrawal modified 433 
the perturbed locomotor behavior observed in a rat model of early alcohol exposure (Marche 434 
et al., 2011). It should be noted that PPARα is highly expressed in tyrosine-hydroxylase 435 
positive neurons and related structures like the striatum (Galán-Rodríguez et al., 2009; Plaza-436 
Zabala et al., 2010). Moreover, both PPARα agonists fenofibrate and tesaglitazar modified the 437 
gene expression profiling of the amygdala and prefrontal cortex, two important brain areas for 438 
reward and dependence directly related with striatum (Ferguson et al., 2014).  In this regard, 439 
several data (present study; Bilbao et al., 2016) suggest that alcohol effects appear to rely on 440 
specific mechanisms related to PPARα signaling in the basal ganglia as alcohol increased the 441 
OEA levels, the gene expression of OEA-synthesizing enzyme Nape-pld, the number of 442 
PPARα-immunoreactive neurons and damage cell activity (FosB) in the striatum. 443 
OEA also plays a central role in the regulation of cell survival and neuroprotection as it is 444 
synthesized on demand by local stimuli that accumulates in the brain after neurotoxic insults 445 
related to cellular stress and tissue damage (Walter et al., 2002; Schäbitz et al., 2002; Ouk et 446 
al., 2014). PPAR activity in brain is relatively high and PPARα is expressed in astrocytes, 447 
microglia and oligodendrocytes (Heneka and Landreth, 2007). In agreement with these 448 
findings, fenofibrate is able to enhance vasculoprotection and anti-inflammatory mechanisms 449 
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to protect against brain ischemia (Ouk et al., 2014), as well as to inhibit hippocampal 450 
microglial activation in whole-brain irradiation (Ramanan et al., 2009). Alcohol-induced brain 451 
damage likely impacts the function of resident immune cells of the central nervous system, 452 
particularly the cytokine production by astrocytes and microglia (Barr et al., 2016). There is 453 
also evidence of long-lasting consequences of hippocampal microglial activation caused by 454 
binge alcohol exposure during adolescence (McClain et al., 2011). Ethanol-induced microglia 455 
activation and neuronal apoptosis is modulated by the innate immunity TLR4 signaling 456 
pathway and enhances NF-kB-related inflammatory mediators (Fernández-Lizarbe et al., 457 
2009, 2013; Alfonso-Loeches and Guerri, 2011; Crews et al., 2013). Interestingly, a recent 458 
study reported that OEA blocked several neuroimmune danger signaling pathways induced by 459 
ethanol binge administration such as HMGB1, TLR4 and the NF-kB proinflammatory 460 
cascades in the rat frontal cortex (Anton et al., 2016). Regarding the present study, OEA 461 
treatment during prolonged ethanol exposure modulates resident neuroimmune cells in the 462 
striatum as it increased the number of activated microglia (Iba-1+ cells and iNOS+ cells) and 463 
reduced the activated astroglia (vimentin immunoreactivity) (Fig. 9A). Despite previous 464 
studies suggesting the lack of induction of apoptosis by OEA, compared to AEA, in human 465 
neuroblastoma cells (Maccarrone and Finazzi-Agró, 2003), recent data demonstrated that 466 
OEA dose-dependently increased cell cytotoxicity and favored a decrease in cell viability in 467 
murine N1E-115 neuroblastoma cells (Hamtiaux et al., 2011). Our results clearly indicated an 468 
enhancement of apoptosis, as OEA increased ethanol-induced apoptosis (cleaved caspase 3+ 469 
cells) in the rat striatum. It has been documented that chronic microglial activation may 470 
contribute to an incorrect response to neuronal injury by removing damaged cells via 471 
phagocytosis (Dheen et al., 2007), an effect that could be enhanced by OEA-PPARα 472 
interaction in an alcoholic environment. Further studies are needed to elucidate whether the 473 
converging actions between ethanol and PPARα activation in the striatum produce an increase 474 
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in neuronal cell death (associated with ROS and TNFα; Alfonso-Loeches and Guerri, 2011; 475 
Guadagno et al., 2013) or a malfunctioning of microglial activity (neurotoxic substances don´t 476 
amplify the immune TLR4 responses) resulting in a decrease in phagocytic activity as was 477 
previously described by AEA and PEA after focal cerebral ischemia (Franklin et al., 2003). 478 
Varying consequences of adult neurogenesis result from the regulation of proliferation, 479 
differentiation and survival of neural stem/progenitor cells (NSPCs) by addictive drugs. 480 
Alcohol inhibits NSPC proliferation in adult rats exposed to acute and chronic alcohol binge 481 
underlying cognitive dysfunction (Geil et al., 2014). However, survival of new-born NSPCs 482 
in the dentate gyrus was impaired 28 days after chronic but not acute alcohol exposure, an 483 
effect that was likely associated with cell apoptosis (Nixon and Crews, 2002; Herrera et al., 484 
2003). Chronic alcohol exposure was accompanied by an inhibition of neuronal 485 
differentiation (decreased number of immature doublecortin+ cells) and neuronal survival of 486 
new-born NSPCs (reduced number of cells co-labeled with both BrdU and the neuron-specific 487 
marker NeuN) (He et al., 2005; Contet et al., 2014). Converging actions exist between forced 488 
alcohol binge and cannabinoid receptor activation by WIN55,212-2 (2 mg/kg) for 5 days 489 
resulting in reduced NSPC proliferation (Alen et al., 2010). In contrast, a recent study from 490 
our group highlighted that the selective CB2 receptor agonist JWH133 specifically 491 
counteracted the chronic ethanol exposure-induced impairment of NSPC proliferation and 492 
maturation in the main neurogenic niches of the adult rat brain (Rivera et al., 2015b). PPAR 493 
isoforms can directly regulate neuronal cell proliferation, survival and differentiation (Cimini 494 
and Ceru, 2008; Di Giacomo et al., 2017). Specifically, PPARα can be implicated in the 495 
progressive age-associated decline of NSPC proliferation (2, 6 and 18 months), an effect that 496 
was partially compensated in enriched environments when PPARα is lacking (Pérez-Martín et 497 
al., 2016). The present study goes further in the potential role of PPARα in other 498 
neurodegenerative challenges like alcohol exposure in which a loss of neurons is described. 499 
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Thus, the PPARα agonist OEA counteracted the deleterious effect of ethanol on NSPC 500 
proliferation (phospho-H3 and BrdU) and neuronal maturation (β3-tubulin+/BrdU+) in the 501 
SVZ (Fig. 9B). Beside neurogenesis and activation of resting microglial, the present study 502 
also probed the concept of microgliogenesis in adult brain, a critical response in pathological 503 
conditions that has not been fully explored (Barua et al., 2017). We found a reduction in the 504 
number of new-born cells expressing Iba-1 (Iba1+/BrdU+ cells) in the SVZ of alcohol-505 
exposed rats that was not affected after OEA treatment. 506 
Overall, the findings presented here add to the previous described roles of the PPARα agonist 507 
OEA, including the lack of alcohol intake increase and the enhancement of ethanol-induced 508 
hypolocomotion when it was administered during ethanol exposure. OEA is an active 509 
signaling player in the activity of resident immune cells (astrocytes and microglia) affecting 510 
cell apoptosis, which are likely influenced by the impaired effects of ethanol on striatal 511 
PPARα+ cell population. The regulatory effects of OEA on NSPC proliferation and neuronal 512 
maturation in a context of alcohol exposure extend previous evidence suggesting a potential 513 
role of the PPARα signaling system in response to alcohol-specific behavioral and 514 
neurodegenerative alterations. 515 
 516 
5. AUTHOR CONTRIBUTIONS 517 
The authors have declared that no competing interest exists. All authors had full access to all 518 
the data in the study and take responsibility for the integrity of the data and the accuracy of 519 
the data analysis. PR, FRF and JS were responsible for the study concept and design. PR, DS, 520 
EB, AV, SA and LB contributed to the acquisition of data. LB performed the LC-MRM 521 
analysis. PR, AS, FJP, FRF and JS assisted with data analysis and interpretation of findings. 522 
FRF and JS drafted of the manuscript. BL, FRF and JS provided critical revision of the 523 
22 
 
manuscript for important intellectual content, obtained funding and study supervision. All 524 
authors approved final version for publication.  525 
 526 
6. FUNDING 527 
This work was supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Economía y 528 
Competitividad (MINECO) co-funded by UE-ERDF program (JS: PI16/01374; FRF: 529 
PI16/01698); Ministerio de Sanidad, Servicios Sociales e Igualdad and Plan Nacional sobre 530 
Drogas (JS: PNSD2015/047); Consejería de Economía, Innovación y Ciencia, Junta de 531 
Andalucía, UE-ERDF (FRF: CTS-8221); Consejería de Salud, Junta de Andalucía, UE-ERDF 532 
(FRF: SAS111224; PR: PI-0337-2012); German Research Foundation DFG (BL: FOR926, 533 
project CP1). FJP (CP14/00212) and AS (CP14/00173) are recipients of a research contract 534 
from “Miguel Servet” Program of ISCIII, EU-ERDF. JS holds a “Miguel Servet II” research 535 
contract from the National System of Health, ISCIII, EU-ERDF, FIMABIS (CPII17/00024). 536 
PR holds a “Sara Borrel” research contract from ISCIII, EU-ERDF (CD16/00067). 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
23 
 
7. REFERENCE 549 
Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, 550 
Guzmán M, Galve-Roperh I. 2005. The endocannabinoid system drives neural 551 
progenitor proliferation. FASEB J 19:1704-6. 552 
Alén F, Mouret A, Viveros MP, Llorente R, Lepousez G, Lledo PM, López-Moreno JA. 553 
Converging action of alcohol consumption and cannabinoid receptor activation on 554 
adult hippocampal neurogenesis. Int J Neuropsychopharmacol. 2010 Mar;13(2):191-555 
205. doi: 10.1017/S1461145709991118. 556 
Alfonso-Loeches S, Guerri C. Molecular and behavioral aspects of the actions of alcohol on 557 
the adult and developing brain. Crit Rev Clin Lab Sci. 2011 Jan-Feb;48(1):19-47. doi: 558 
10.3109/10408363.2011.580567. 559 
Antón M, Alén F, Gómez de Heras R, Serrano A, Pavón FJ, Leza JC, García-Bueno B, 560 
Rodríguez de Fonseca F, Orio L. Oleoylethanolamide prevents neuroimmune 561 
HMGB1/TLR4/NF-kB danger signaling in rat frontal cortex and depressive-like 562 
behavior induced by ethanol binge administration. Addict Biol. 2017 May;22(3):724-563 
741. doi: 10.1111/adb.12365. 564 
Bandiera T, Ponzano S, Piomelli D. 2014. Advances in the discovery of N-acylethanolamine 565 
acid amidase inhibitors. Pharmacol Res 86:11-7. doi:10.1016/j.phrs.2014.04.011. 566 
Barr T, Helms C, Grant K, Messaoudi I. Opposing effects of alcohol on the immune system. 567 
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:242-51. doi: 568 
10.1016/j.pnpbp.2015.09.001. 569 
Barson JR, Karatayev O, Chang GQ, Johnson DF, Bocarsly ME, Hoebel BG, Leibowitz SF. 570 
Positive relationship between dietary fat, ethanol intake, triglycerides, and 571 
hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol. 2009 572 
Sep;43(6):433-41. doi: 10.1016/j.alcohol.2009.07.003. 573 
Barua S, Chung JI, Kim AY, Lee SY, Lee SH, Baik EJ. Jak kinase 3 signaling in 574 
microgliogenesis from the spinal nestin+ progenitors in both development and 575 
response to injury. Neuroreport. 2017 Sep 27;28(14):929-935. 576 
doi:10.1097/WNR.0000000000000854. 577 
Bilbao A, Blanco E, Luque-Rojas MJ, Suárez J, Palomino A, Vida M, Araos P, Bermúdez-578 
Silva FJ, Fernández-Espejo E, Spanagel R, Rodríguez de Fonseca F. 579 
Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through 580 
a PPARα receptor-independent mechanism. Addict Biol. 2013 Jan;18(1):78-87. 581 
doi:10.1111/adb.12006. 582 
Bilbao A, Serrano A, Cippitelli A, Pavón FJ, Giuffrida A, Suárez J, García-Marchena N, 583 
Baixeras E, Gómez de Heras R, Orio L, Alén F, Ciccocioppo R, Cravatt BF, Parsons 584 
LH, Piomelli D, Rodríguez de Fonseca F. Role of the satiety factor 585 
oleoylethanolamide in alcoholism. Addict Biol. 2016 Jul;21(4):859-72. 586 
doi:10.1111/adb.12276 587 
Bindila L and Lutz B. Extraction and Simultaneous Quantification of Endocannabinoids and 588 
Endocannabinoid-Like Lipids in Biological Tissues. Methods in Molecular Biology, 589 
2016; 1412:9-18 590 
24 
 
Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, Fu J, McGaugh JL, Piomelli 591 
D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. 592 
Proc Natl Acad Sci U S A. 2009 May 12;106(19):8027-31. 593 
doi:10.1073/pnas.0903038106. 594 
Cimini A, Cerù MP. Emerging roles of peroxisome proliferator-activated receptors (PPARs) 595 
in the regulation of neural stem cells proliferation and differentiation. Stem Cell Rev. 596 
2008 Dec;4(4):293-303. doi:10.1007/s12015-008-9024-2. 597 
Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A, De Fonseca FR, 598 
Piomelli D, Ciccocioppo R. 2008. Increase of brain endocannabinoid anandamide 599 
levels by FAAH inhibition and alcohol abuse behaviours in the rat. 600 
Psychopharmacology (Berl) 198:449-60. doi: 10.1007/s00213-008-1104-0. 601 
Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. 2005. Endocannabinoid system and 602 
alcohol addiction: pharmacological studies. Pharmacol Biochem Behav 81:369-80. 603 
Contet C, Kim A, Le D, Iyengar SK, Kotzebue RW, Yuan CJ, Kieffer BL, Mandyam CD. μ-604 
Opioid receptors mediate the effects of chronic ethanol binge drinking on the 605 
hippocampal neurogenic niche. Addict Biol. 2014 Sep;19(5):770-80. 606 
doi:10.1111/adb.12040. 607 
Crews FT, Qin L, Sheedy D, Vetreno RP, Zou J. High mobility group box 1/Toll-like receptor 608 
danger signaling increases brain neuroimmune activation in alcohol dependence. Biol 609 
Psychiatry. 2013 Apr 1;73(7):602-12. doi:10.1016/j.biopsych.2012.09.030. 610 
Crews FT, Nixon K. 2009. Mechanisms of neurodegeneration and regeneration in alcoholism. 611 
Alcohol Alcohol 44:115-27. doi: 10.1093/alcalc/agn079. 612 
Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. 613 
Curr Med Chem. 2007;14(11):1189-97. 614 
Di Giacomo E, Benedetti E, Cristiano L, Antonosante A, d'Angelo M, Fidoamore A, Barone 615 
D, Moreno S, Ippoliti R, Cerù MP, Giordano A, Cimini A. Roles of PPAR 616 
transcription factors in the energetic metabolic switch occurring during adult 617 
neurogenesis. Cell Cycle. 2017 Jan 2;16(1):59-72. 618 
doi:10.1080/15384101.2016.1252881. 619 
Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the 620 
limelight. Nat Neurosci. 2011 Jan;14(1):9-15. doi: 10.1038/nn.2720. 621 
Ferguson LB, Most D, Blednov YA, Harris RA. PPAR agonists regulate brain gene 622 
expression: relationship to their effects on ethanol consumption. Neuropharmacology. 623 
2014 Nov;86:397-407. doi: 10.1016/j.neuropharm.2014.06.024. 624 
Fernandez-Lizarbe S, Montesinos J, Guerri C. Ethanol induces TLR4/TLR2 association, 625 
triggering an inflammatory response in microglial cells. J Neurochem. 2013 626 
Jul;126(2):261-73. doi: 10.1111/jnc.12276. 627 
Fernandez-Lizarbe S, Pascual M, Guerri C. Critical role of TLR4 response in the activation of 628 
microglia induced by ethanol. J Immunol. 2009 Oct 1;183(7):4733-44. doi: 629 
10.4049/jimmunol.0803590. 630 
Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide 631 
increases after focal cerebral ischemia and potentiates microglial cell motility. J 632 
Neurosci. 2003 Aug 27;23(21):7767-75. 633 
25 
 
Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. 2010. Modulation of the endocannabinoid 634 
system: neuroprotection or neurotoxicity? Exp Neurol 224:37-47. doi: 635 
10.1016/j.expneurol.2010.03.021 636 
Fu J, Dipatrizio NV, Guijarro A, Schwartz GJ, Li X, Gaetani S, Astarita G, Piomelli D. 637 
Sympathetic activity controls fat-induced oleoylethanolamide signaling in small 638 
intestine. J Neurosci. 2011 Apr 13;31(15):5730-6. doi:10.1523/JNEUROSCI.5668-639 
10.2011. 640 
Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, 641 
Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E. 2009. Oleoylethanolamide 642 
exerts partial and dose-dependent neuroprotection of substantia nigra dopamine 643 
neurons. Neuropharmacology 56:653-64. doi:10.1016/j.neuropharm.2008.11.006. 644 
Galve-Roperh I, Chiurchiù V, Díaz-Alonso J, Bari M, Guzmán M, Maccarrone M. 2013. 645 
Cannabinoid receptor signaling in progenitor/stem cell proliferation and 646 
differentiation. Prog Lipid Res 52:633-50. doi:10.1016/j.plipres.2013.05.004. 647 
Garcia-Marchena N, Pavon FJ, Pastor A, Araos P, Pedraz M, Romero-Sanchiz P, Calado M, 648 
Suarez J, Castilla-Ortega E, Orio L, Boronat A, Torrens M, Rubio G, de la Torre R, 649 
Rodriguez de Fonseca F, Serrano A. Plasma concentrations of oleoylethanolamide and 650 
other acylethanolamides are altered in alcohol-dependent patients: effect of length of 651 
abstinence. Addict Biol. 2017 Sep;22(5):1366-1377. doi: 10.1111/adb.12408. 652 
Geil CR, Hayes DM, McClain JA, Liput DJ, Marshall SA, Chen KY, Nixon K. Alcohol and 653 
adult hippocampal neurogenesis: promiscuous drug, wanton effects. Prog 654 
Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:103-13. 655 
doi:10.1016/j.pnpbp.2014.05.003. 656 
Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, 657 
Pollard S, Yáñez-Muñoz RJ, Williams G, Walsh FS, Pangalos MN, Doherty P. 2008. 658 
A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone 659 
neurogenesis in an age-dependent manner. Mol Cell Neurosci 38:526-36. 660 
Guadagno J, Xu X, Karajgikar M, Brown A, Cregan SP. Microglia-derived TNFα induces 661 
apoptosis in neural precursor cells via transcriptional activation of the Bcl-2 family 662 
member Puma. Cell Death Dis. 2013 Mar 14;4:e538. doi:10.1038/cddis.2013.59. 663 
Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide 664 
stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-665 
activated receptor alpha (PPAR-alpha). J Biol Chem. 2004 Jul 2;279(27):27849-54. 666 
Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM. 2011. 667 
Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma 668 
cells through inhibition of their metabolism. PLoS One 6:e26823. doi: 669 
10.1371/journal.pone.0026823. 670 
He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, 671 
Ron D. Glial cell line-derived neurotrophic factor mediates the desirable actions of the 672 
anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005 Jan 673 
19;25(3):619-28. 674 
Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007 675 
Aug;1771(8):1031-45. 676 
26 
 
Herrera DG, Yague AG, Johnsen-Soriano S, Bosch-Morell F, Collado-Morente L, Muriach 677 
M, Romero FJ, Garcia-Verdugo JM. 2003. Selective impairment of hippocampal 678 
neurogenesis by chronic alcoholism: protective effects of an antioxidant. Proc Natl 679 
Acad Sci U S A 100:7919-24. 680 
Katona I, Freund TF. 2012. Multiple functions of endocannabinoid signaling in the brain. 681 
Annu Rev Neurosci 35:529-58. doi:10.1146/annurev-neuro-062111-150420. 682 
Le Foll B, Di Ciano P, Panlilio LV, Goldberg SR, Ciccocioppo R. Peroxisome proliferator-683 
activated receptor (PPAR) agonists as promising new medications for drug addiction: 684 
preclinical evidence. Curr Drug Targets. 2013 Jun;14(7):768-76. 685 
Lomazzo E, Bindila L, Remmers F, Lerner R, Schwitter C, Hoheisel U, Lutz B. 2014. 686 
Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of 687 
stress-related hyperalgesia in an animal model of chronic pain. 688 
Neuropsychopharmacology. Aug 6. doi: 10.1038/npp.2014.198. 689 
LoVerme J, Guzmán M, Gaetani S, Piomelli D. Cold exposure stimulates synthesis of the 690 
bioactive lipid oleoylethanolamide in rat adipose tissue. J Biol Chem. 2006 Aug 691 
11;281(32):22815-8. 692 
Maccarrone M, Finazzi-Agró A. 2003. The endocannabinoid system, anandamide and the 693 
regulation of mammalian cell apoptosis. Cell Death Differ 10:946-55. 694 
Marche K, Danel T, Bordet R. Fetal alcohol-induced hyperactivity is reversed by treatment 695 
with the PPARα agonist fenofibrate in a rat model. Psychopharmacology (Berl). 2011 696 
Mar;214(1):285-96. doi:10.1007/s00213-010-1960-2. 697 
Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, 698 
Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR. 699 
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome 700 
proliferator-activated receptors. Biol Psychiatry. 2011 Apr 1;69(7):633-41. doi: 701 
10.1016/j.biopsych.2010.07.009. 702 
McClain JA, Morris SA, Deeny MA, Marshall SA, Hayes DM, Kiser ZM, Nixon K. 703 
Adolescent binge alcohol exposure induces long-lasting partial activation of microglia. 704 
Brain Behav Immun. 2011 Jun;25 Suppl 1:S120-8. doi:10.1016/j.bbi.2011.01.006. 705 
Nixon K, Crews FT. Binge ethanol exposure decreases neurogenesis in adult rat 706 
hippocampus. J Neurochem. 2002 Dec;83(5):1087-93. 707 
Nixon K, Crews FT. 2004. Temporally specific burst in cell proliferation increases 708 
hippocampal neurogenesis in protracted abstinence from alcohol. J Neurosci 24:9714-709 
22. 710 
Orio L, Pavón FJ, Blanco E, Serrano A, Araos P, Pedraz M, Rivera P, Calado M, Suárez J, de 711 
Fonseca FR. Lipid transmitter signaling as a new target for treatment of cocaine 712 
addiction: new roles for acylethanolamides and lysophosphatidic acid. Curr Pharm 713 
Des. 2013;19(40):7036-49. 714 
Ouk T, Gautier S, Pétrault M, Montaigne D, Maréchal X, Masse I, Devedjian JC, Deplanque 715 
D, Bastide M, Nevière R, Duriez P, Staels B, Pasquier F, Leys D, Bordet R. Effects of 716 
the PPAR-α agonist fenofibrate on acute and short-term consequences of brain 717 
ischemia. J Cereb Blood Flow Metab. 2014 Mar;34(3):542-51. 718 
doi:10.1038/jcbfm.2013.233. 719 
27 
 
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, 720 
Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C. 2006 721 
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in 722 
the discovery of small-molecule hypophagic agents. Cell Metab. 3: 167-75. 723 
Paxinos G and Watson C. 2007. The rat brain in stereotaxic coordinates. Sidney: Academic 724 
Press. Sixth edition. 725 
Pérez-Martín M, Rivera P, Blanco E, Lorefice C, Decara J, Pavón FJ, Serrano A, Rodríguez 726 
de Fonseca F, Suárez J. Environmental enrichment, age, and PPARα interact to 727 
regulate proliferation in neurogenic niches. Front Neurosci. 2016 Mar 9;10:89. doi: 728 
10.3389/fnins.2016.00089. 729 
Pertwee RG. 2008. Ligands that target cannabinoid receptors in the brain: from THC to 730 
anandamide and beyond. Addict Biol 13:147-59. 731 
Piomelli D. A fatty gut feeling. Trends Endocrinol Metab. 2013 Jul;24(7):332-41. doi: 732 
10.1016/j.tem.2013.03.001. 733 
Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, 734 
Parrott JA, Putman D. 2006. Pharmacological profile of the selective FAAH inhibitor 735 
KDS-4103 (URB597). CNS Drug Rev 12:21-38. 736 
Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, 737 
Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P. Effects of the 738 
endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive 739 
deficits in mice. Synapse. 2010 May;64(5):379-89. doi:10.1002/syn.20733. 740 
Ramanan S, Kooshki M, Zhao W, Hsu FC, Riddle DR, Robbins ME. The PPARalpha agonist 741 
fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation 742 
after whole-brain irradiation. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):870-7. 743 
doi: 10.1016/j.ijrobp.2009.06.059. 744 
Rivera P, Arrabal S, Vargas A, Blanco E, Serrano A, Pavón FJ, Rodríguez de Fonseca F, 745 
Suárez J. Localization of peroxisome proliferator-activated receptor alpha (PPARα) 746 
and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) in cells 747 
expressing the Ca(2+)-binding proteins calbindin, calretinin, and parvalbumin in the 748 
adult rat hippocampus. Front Neuroanat. 2014 Mar 17;8:12. 749 
doi:10.3389/fnana.2014.00012. 750 
Rivera P, Bindila L, Pastor A, Pérez-Martín M, Pavón FJ, Serrano A, de la Torre R, Lutz B, 751 
Rodríguez de Fonseca F, Suárez J. Pharmacological blockade of the fatty acid amide 752 
hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat 753 
hippocampus, hypothalamus and striatum in a negative energy context. Front Cell 754 
Neurosci. 2015 Mar 27;9:98. doi: 10.3389/fncel.2015.00098. 755 
Rivera P, Blanco E, Bindila L, Alen F, Vargas A, Rubio L, Pavón FJ, Serrano A, Lutz B, 756 
Rodríguez de Fonseca F, Suárez J. Pharmacological activation of CB2 receptors 757 
counteracts the deleterious effect of ethanol on cell proliferation in the main 758 
neurogenic zones of the adult rat brain. Front Cell Neurosci. 2015 Sep 29;9:379. doi: 759 
10.3389/fncel.2015.00379. 760 
Rivera P, Pérez-Martín M, Pavón FJ, Serrano A, Crespillo A, Cifuentes M, López-Ávalos 761 
MD, Grondona JM, Vida M, Fernández-Llebrez P, de Fonseca FR, Suárez J. 762 
Pharmacological administration of the isoflavone daidzein enhances cell proliferation 763 
28 
 
and reduces high fat diet-induced apoptosis and gliosis in the rat hippocampus. PLoS 764 
One. 2013 May 31;8(5):e64750. doi:10.1371/journal.pone.0064750. 765 
Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D. 766 
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis 767 
study. Stroke. 2002 Aug;33(8):2112-4. 768 
Serrano A, Pavón FJ, Tovar S, Casanueva F, Señarís R, Diéguez C, de Fonseca FR. 769 
Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating 770 
food intake. Neuropharmacology. 2011 Mar;60(4):593-601. doi: 771 
10.1016/j.neuropharm.2010.12.007. 772 
Serrano A, Rivera P, Pavón FJ, Decara J, Suárez J, Rodríguez de Fonseca F, Parsons LH. 773 
2012. Differential effects of single versus repeated alcohol withdrawal on the 774 
expression of endocannabinoid system-related genes in the rat amygdala. Alcohol Clin 775 
Exp Res 36:984-994. doi: 10.1111/j.1530-0277.2011.01686.x. 776 
Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty 777 
acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A. 778 
2002 Jun 11;99(12):8394-9. 779 
Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive 780 
behavior. Physiol Rev. 2009 Apr;89(2):649-705. doi:10.1152/physrev.00013.2008. 781 
Stella N. 2010. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and 782 
astrocytomas. Glia 58:1017-30. doi: 10.1002/glia.20983. 783 
Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical 784 
neurons. Eur J Pharmacol. 2001 Aug 17;425(3):189-96. 785 
Suárez J, Rivera P, Arrabal S, Crespillo A, Serrano A, Baixeras E, Pavón FJ, Cifuentes M, 786 
Nogueiras R, Ballesteros J, Dieguez C, Rodríguez de Fonseca F. Oleoylethanolamide 787 
enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte 788 
phenotype in epididymal white adipose tissue in rat. Dis Model Mech. 2014 789 
Jan;7(1):129-41. doi: 10.1242/dmm.013110. 790 
Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limón P, Ren X, Lam TT, Schwartz GJ, 791 
de Araujo IE. A gut lipid messenger links excess dietary fat to dopamine deficiency. 792 
Science. 2013 Aug 16;341(6147):800-2. doi:10.1126/science.1239275. 793 
Ueda N, Tsuboi K, Uyama T. 2010. Enzymological studies on the biosynthesis of N-794 
acylethanolamines. Biochim Biophys Acta 1801:1274-85. 795 
Walter L, Franklin A, Witting A, Moller T, Stella N. Astrocytes in culture produce 796 
anandamide and other acylethanolamides. J Biol Chem. 2002 Jun 7;277(23):20869-76. 797 
 798 
 799 
 800 
 801 
 802 
 803 
29 
 
8. LEGENDS TO FIGURES 804 
Figure 1. Experimental design of chronic ethanol exposure (10%) for 2 weeks (A) in order to 805 
evaluate ethanol consumption (B), distance covered in the open field (OF) (C), blood ethanol 806 
concentration (BEC), plasma levels of the hepatic enzymes gamma-glutamyl transpeptidase 807 
(γGT), glutamate pyruvate transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) 808 
(D), plasma (D) and brain (E) levels of the endocannabinoids oleoylethanolamide (OEA) and 809 
anandamide (AEA), and mRNA levels of Cnr1, Ppar, Nape-pld and Faah in the striatum 810 
(F). The histograms represent the mean + s.e.m. (n=6) per experimental group. Bonferroni’s 811 
or Student’s t test: */**/***P<0.05/0.01/0.001 vs. sucrose diet-per fed group. 812 
 813 
Figure 2. Experimental design of OEA and AEA i.p. administration (10 mg/kg) during the 814 
last 5 days of chronic ethanol exposure (10%) for 2 weeks (A) in order to evaluate sucrose (B) 815 
and ethanol (C) consumption, total distance covered in OF (D), distance covered in time bins 816 
of 5 minutes (E, F), plasma levels of the hepatic γGT and the GPT/GOT ratio (G), and plasma 817 
levels of the endocannabinoids OEA and AEA (H). The histograms represent the mean + 818 
s.e.m. (n=6) per experimental group. Bonferroni’s test: */**/***P<0.05/0.01/0.001 vs. 819 
vehicle-sucrose group; 
#/##/###
P<0.05/0.01/0.001 vs. vehicle-ethanol group; 
$
P<0.05 vs. OEA-820 
sucrose group. 821 
 822 
Figure 3. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 823 
chronic ethanol exposure (10%) for 2 weeks on GFAP, vimentin, Iba-1 and iNOS 824 
immunohistochemistry in the striatum. The histograms represent the mean + s.e.m. per area 825 
(mm
2
) (n=6) of the number of GFAP+ cells (A), vimentin immunoreactivity (F), the number 826 
of Iba-1+ cells (K) and the number of iNOS+ cells (P) per experimental group.  Bonferroni’s 827 
test: *P<0.05 vs. vehicle-sucrose group; 
#/##/###
P<0.05/0.01/0.001 vs. vehicle-ethanol group. 828 
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Representative microphotographs showing low and high (insets) magnification views of the 829 
respective immunostaining (B-E, G-J, L-O, Q-T). Scale bars are included in each image. Str, 830 
striatum; lv, lateral ventricle. 831 
 832 
Figure 4. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 833 
chronic ethanol exposure (10%) for 2 weeks on FosB and cleaved caspase 3 834 
immunohistochemistry in the striatum. The histograms represent the mean + s.e.m. per area 835 
(mm
2
) (n=6) of the number of FosB+ cells (A) and cleaved caspase 3+ cells (F) per 836 
experimental group. Bonferroni’s test: **P<0.01 vs. vehicle-sucrose group; #P<0.05 vs. 837 
vehicle-ethanol group. Representative microphotographs showing low and high (insets) 838 
magnification views of the respective immunostaining (B-E, G-J). Scale bars are included in 839 
each image. Str, striatum; lv, lateral ventricle. 840 
 841 
Figure 5. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 842 
chronic ethanol exposure (10%) for 2 weeks on the immunofluorescent co-expression of 843 
cleaved caspase 3, GFAP and Iba-1 in striatal cells. The histograms represent the mean + 844 
s.e.m. per area (mm
2
) (n=6) of the number of GFAP+/cleaved caspase 3+ cells (A) and 845 
Iba1+/cleaved caspase 3+ cells (F) per experimental group. Bonferroni’s test: **P<0.01 vs. 846 
vehicle-sucrose group; 
#
P<0.05 vs. vehicle-ethanol group. High resolution confocal laser 847 
scanning photomicrographs showing the respective co-labeling (B-E, G-J). Arrowheads 848 
indicate cleaved caspase 3+ cells expressing GFAP or Iba1. Scale bars indicated 25 m. 849 
 850 
Figure 6. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 851 
chronic ethanol exposure (10%) for 2 weeks on the immunofluorescent co-expression of 852 
PPARα, cleaved caspase 3 and Iba1 in striatal cells. The histograms represent the mean + 853 
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s.e.m. per area (mm
2
) (n=6) of the number of PPARα+ cells (A), PPARα+/cleaved caspase 3+ 854 
cells (F) and PPARα+/Iba1+ cells (K) per experimental group. Bonferroni’s test: 855 
*/***P<0.05/0.001 vs. vehicle-sucrose group; 
###
P<0.001 vs. vehicle-ethanol group. High 856 
resolution confocal laser scanning photomicrographs showing the respective co-labeling (B-857 
E, G-J, L-O). Arrows indicate PPARα+ cells expressing cleaved caspase 3 or Iba1.  Scale 858 
bars indicated 25 m. 859 
 860 
Figure 7. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 861 
chronic ethanol exposure (10%) for 2 weeks on phospho-histone H3 (Ser-10) and 5´-bromo-862 
2´-deoxyuridine (BrdU) immunohistochemistry in the SVZ. The histograms represent the 863 
mean + s.e.m. per area (mm
2
) (n=6) of the number of phospho-H3
+
 cells (A) and BrdU+ cells 864 
(F) per experimental group. Bonferroni’s test: *P<0.05 vs. vehicle-sucrose group; ##P<0.01 865 
vs. vehicle-ethanol group. Representative microphotographs showing low and high (insets) 866 
magnification views of the respective immunostaining (B-E, G-J). Scale bars are included in 867 
each image. Str, striatum; lv, lateral ventricle. 868 
 869 
Figure 8. Effects of OEA and AEA i.p. administration (10 mg/kg) during the last 5 days of 870 
chronic ethanol exposure (10%) for 2 weeks on the immunofluorescent co-labeling of BrdU, 871 
GFAP, β3-tubulin and Iba1 in cells of the SVZ. The histograms represent the mean + s.e.m. 872 
per area (mm
2
) (n=6) of the number of GFAP+/BrdU+ cells (A), β3-tubulin+/BrdU+ cells (F) 873 
and Iba1+/BrdU+ cells (K). Bonferroni’s test: */***P<0.05/0.001 vs. vehicle-sucrose group; 874 
#/##
P<0.05/0.01 vs. vehicle-ethanol group. High resolution confocal laser scanning 875 
photomicrographs showing the respective co-labeling (B-E, G-J, L-O). Arrowheads indicate 876 
BrdU+ cells expressing GFAP, β3-tubulin or Iba1.  Scale bars indicated 25 m. 877 
 878 
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Figure 9. Schematic drawing that summarize the effects of ethanol and OEA on astroglial and 879 
microglial activity (A), and NSPC proliferation and neuronal maturation (B). 880 
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